Shield Therapeutics PLC saw its shares rise 11% after reporting a significant reduction in half-year losses and reaffirming its goal to achieve operating profitability in 2026. The company's revenue increased 42% to $30.4 million, driven by US sales of its iron-deficiency treatment Accrufer, a development milestone from its Chinese partner, and higher royalties. Despite tighter Medicaid rules in New York, US prescriptions grew 21%, with a strategic shift to commercially insured patients. The company ended the period with $8.3 million in cash and expects continued growth, including new contracts and clinical trials, while Peel Hunt maintains a 'buy' rating with a 15p price target, seeing potential for shares to triple if profitability is reached.
Memory and storage stocks including Micron, SanDisk, and Western Digital dropped 5-7% due to rising U.S. Treasury yields increasing the cost of capital and discount rates on future earnings. This selloff is a valuation reset after a strong 2026 rally...
Jim Cramer highlighted the booming memory and storage sector, specifically predicting Micron Technology's stock could double again, provided there is no slowdown in AI data center demand. He argues this cycle is different due to strong long-term cust...
Jim Cramer highlighted that the AI boom has transformed the memory chip industry, supporting strong profits amid soaring demand and disciplined supply. Despite huge rallies this year—Sandisk up 653%, Seagate 261%, Micron 254%, Western Digital 211%—Cr...
Shares of memory and storage chipmakers rose sharply after reports that the US government is urging domestic tech firms to avoid purchasing conventional memory chips from Chinese suppliers. Micron Technology, Sandisk, Western Digital, and Seagate all...
Memory and storage stocks like SanDisk, Western Digital, and Micron surged Monday following Tesla CEO Elon Musk's comments highlighting memory as a key bottleneck for AI development. This rally is supported by SanDisk's strong long-term growth plan, ...
